ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 2661 • ACR Convergence 2025

    Heterogeneity of RA-ILD by Longitudinal Forced Vital Capacity Measurements Is Associated with Survival and Respiratory Hospitalization

    Bryant England1, Yangyuna Yang1, Punyasha Roul2, Tate Johnson1, Scott Matson3, Grant Cannon4, Brian Sauer5, Jeffrey Curtis6, Joshua Baker7 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, NE, 3University of Kansas, Kansas City, MO, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Forced vital capacity (FVC) is one of the primary disease measures monitored in RA-associated interstitial lung disease (RA-ILD). While prior studies have suggested a…
  • Abstract Number: 2235 • ACR Convergence 2025

    Proportion of Early Rheumatoid Arthritis Patients with Improved, Stable, or Worsened Lung Function Over 1-Year: Results from a Multicenter, Prospective Cohort Study

    Erica Mulcaire-Jones1, Suiyuan Huang1, Xiaosong Wang2, Misti Paudel3, Ying Qi4, Grace Qian5, Liya Sisay Getachew6, Emily Kowalski6, Kevin Mueller5, Alene Saavedra5, Lauren O'Keeffe5, Natalie Davis7, Alison Puri8, Kathleen Vanni5, Caleb Bolden9, Tina Mahajan10, Marzieh Jamali1, Pierre Antoine Juge11, Tracy J. Doyle12, Marcy Bolster13, Kevin Deane14, Raul San Jose Estepar5, George Washko5, Gregory McDermott7, Bryant England10, Jeffrey Sparks6 and Dinesh Khanna1, 1University of Michigan, Ann Arbor, MI, 2Brigham and Women's Hospital, Natick, MA, 3Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 4Brigham and Women’s Hospital, Boston, 5Brigham and Women's Hospital, Boston, 6Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital, Brookline, MA, 8Boston University, Brookline, MA, 9Massachusetts General Hospital, Boston, 10University of Nebraska Medical Center, Omaha, NE, 11Hopital Bichat, APHP, Paris, France, 12Brigham and Women's Hospital, West Roxbury, MA, 13Massachusetts General Hospital, Concord, MA, 14University of Colorado Denver Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Several lung diseases are associated with rheumatoid arthritis (RA), including interstitial lung disease (ILD) and emphysema. In RA-ILD baseline lung function and decline in…
  • Abstract Number: 1951 • ACR Convergence 2025

    Quantitative HRCT Analysis in Sjögren’s Disease-associated ILD: CALIPER-Derived Imaging Biomarkers for Prognostic Assessment

    Gaetano La Rocca1, Francesco Ferro2, Vincenzo Uggenti3, Beatrice Dei4, Giovanni Fulvio4, Michele Moretti4, Marta Mosca5, Chiara Romei3 and Chiara Baldini5, 1University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, 2Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 3University of Pisa, 2nd Radiology Unit, Pisa, Italy, 4Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, 5University of Pisa, Pisa, Pisa, Italy

    Background/Purpose: Interstitial Lung Disease (ILD) is a frequent manifestation of Sjögren’s Disease (SjD), associated with significant morbidity and mortality. However, data on the prevalence of…
  • Abstract Number: 1663 • ACR Convergence 2025

    Tocilizumab for acute exacerbation of rheumatic disease-related interstitial lung disease: A prospective real-world study

    Wenwen Xu1, Yiyangzi Ma2, Shuang Ye3 and Qiong Fu2, 1Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), 2Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), 3Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)

    Background/Purpose: Acute exacerbation (AE) of rheumatic disease-related interstitial lung disease (RD-ILD) is a severe and potentially life-threatening condition, while there remains no clear consensus of…
  • Abstract Number: 1390 • ACR Convergence 2025

    Cystic Lung Disease and Autoantibodies in Lymphocytic Interstitial Pneumonia: Exploring the Impact of Sjögren’s Syndrome

    KARLA CHACON1, ALBERTO ALEJANDRO MARQUEZ-SANCHEZ1, Jorge Rojas-Serrano2 and MAYRA MEJÍA1, 1Instituto Nacional de Enfermedades Respiratorias, CIUDAD DE MEXICO, Distrito Federal, Mexico, 2Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico

    Background/Purpose: Lymphocytic interstitial pneumonia (LIP) is a rare interstitial lung disease, most commonly associated with Sjögren’s syndrome, but it may also occur in the context…
  • Abstract Number: 1193 • ACR Convergence 2025

    Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis

    Angela Chang1, Navid Saleh1, Alec Yu1, Darya S. Jalaledin2, Sabrina Hoa3, Robert Levy4, Jennifer Wilson5, Charles Poirier6, John Yee1, James Choi1, Océane Landon-Cardinal7, Hyein Kim8 and Kun Huang9, 1University of British Columbia, Vancouver, BC, Canada, 2Université de Montréal, Saint-Lambert, QC, Canada, 3University of Montreal, Brossard, QC, Canada, 4University of British Columbia, Deerfield, IL, 5UBC, Vancouver, BC, Canada, 6University of Montreal, Montreal, QC, Canada, 7Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 8The University of British Columbia, Vancouver, BC, Canada, 9University of British Columbia, Vancouver, Surrey, BC, Canada

    Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of idiopathic inflammatory myositis (IIM) and systemic sclerosis (SSc), ranging from subclinical ILD to rapidly progressive…
  • Abstract Number: 0678 • ACR Convergence 2025

    Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients

    Andrea-Hermina Györfi1, Ayla Nadja Stuetz2, Christina Duesing3, Laura-Marie Lahu4, Franca Sophie Deicher5, Yi-Nan Li6, Celine van Saan5, Alexandru-Emil Matei7, Alexander Hoelscher5, Peter-Martin Bruch8, Sarah Koziel8, Manuel Roehrich9, Mareike Cramer10, Bernhard Homey5, Bjoern Buehring11, Alexander Kreuter12, Aleksandar Radujkovic5, Claus Peter Heußel13, Hanns-Martin Lorenz14, Ricardo Grieshaber-Bouyer15, Georg Schett16, Jörg Distler17 and Wolfgang Merkt18, 1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, 2Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, 3Klinik für Rheumatologie, Düsseldorf, Germany, 4Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, 5Uniklinik Düsseldorf, Düsseldorf, Germany, 6University Hospital of Düsseldorf, Düsseldorf, Germany, 7Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, 8University Hospital Düsseldorf, Dusseldorf, Germany, 9Universitätsmedizin Mainz, Mainz, 10University Hospital Düsseldorf, Düsseldorf, Germany, 11Bergisches Rheuma-Zentrum, Krankenhaus St Josef, Wuppertal, Germany, 12HELIOS St. Elisabeth Clinic Oberhausen, University Witten-Herdecke, Oberhausen, Germany, 13Thoraxklinik, University of Heidelberg, Heidelberg, 14Universitétsklinikum Heidelberg, Heidelberg, Germany, 15University Hospital Erlangen, Erlangen, Germany, 16Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 17University Hospital Duesseldorf and HHU, Duesseldorf, Germany, 18University Hospital Düsseldorf, Düsseldorf, Germany

    Background/Purpose: Systemic sclerosis (SSc) possesses the highest case-related mortality of all rheumatic diseases. B cell-targeting, including CD19-targeting CAR-T cells, has shown efficacy but failed to…
  • Abstract Number: 0161 • ACR Convergence 2025

    Risk Factors and Clinical Predictors of Lung Cancer in Systemic Sclerosis: A Matched Case-Control Study from a Michigan Cohort

    Madiha Naqsh Siddiqui1, Yen Chen1, Rosemary Gedert2, Suiyuan Huang2, Dinesh Khanna2 and John Varga2, 1University of Michigan, Ann Arbor, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: Malignancies are one of the leading causes of non-systemic sclerosis-related mortality in patients with systemic sclerosis (SSc)1, with lung cancer being the most common…
  • Abstract Number: 2611 • ACR Convergence 2025

    Exploring the Role of a Lung Ultrasound Score in the Assessment of Severity of Connective Tissue Disease-Related Interstitial Lung Disease

    jin ding1, ying zhang1, Linxuan Pang1, ning guo2 and zhaohui zheng1, 1Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic), 2Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic)

    Background/Purpose: The role of lung ultrasound (LUS) in assessing disease severity of interstitial lung disease (ILD) remains unclear. We employed a semiquantitative scoring system to…
  • Abstract Number: 2230 • ACR Convergence 2025

    Racial and Ethnic Disparities in Rheumatoid Arthritis-Associated Interstitial Lung Disease and Their Impact on Antifibrotic Therapy

    Andrea Galecio Chao, Baylor College of Medicine, Houston, TX

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a significant cause of morbidity and mortality among patients with rheumatoid arthritis (RA), often leading to progressive…
  • Abstract Number: 1946 • ACR Convergence 2025

    Quantitative Imaging Analysis of Chest Computed Tomography in Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Emily Anthone1, Emily Wan2, Aimee Schreiner1, Katherine Wysham3, Gary Kunkel4, Grant Cannon5, Andreas Reimold6, John Richards7, Dana Ascherman8, Gail Kerr9, Paul Monach10, Halie Frideres11, Punyasha Roul12, Scott Matson13, Joshua Baker14, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2VA Boston, Omaha, NE, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 5University of Utah and Salt Lake City VA, Salt Lake City, UT, 6Dallas VA Medical Center, Dallas, TX, 7Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 8University of Pittsburgh, Pittsburgh, PA, 9Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 10VA Boston Healthcare System, Boston, MA, 11UNMC Department of Rheumatology, Omaha, NE, 12UNMC, Omaha, NE, 13University of Kansas, Kansas City, MO, 14University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Interstitial lung disease (ILD) frequently complicates the disease course in RA. While forced vital capacity (FVC) from pulmonary function tests (PFTs) is the most…
  • Abstract Number: 1664 • ACR Convergence 2025

    Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression

    Alexia Zagouras1, Sammy Pickell1, Yuhan Liu1, Ronald Witteles1 and Matthew Charles Baker2, 1Stanford University, Stanford, CA, 2Stanford University, Menlo Park, CA

    Background/Purpose: There are no FDA-approved therapies for cardiac sarcoidosis (CS), a disease associated with high morbidity and mortality. Treatment typically consists of glucocorticoids and off-label…
  • Abstract Number: 1382 • ACR Convergence 2025

    Interstitial lung disease in primary sjögren syndrome: pathochrony, seronegative cases, and Risk of progressive pulmonary fibrosis

    Delia Reina1, Paula Estrada-Alarcón2, Daniel Roig-Vilaseca1, Dacia Cerdà1, Vanessa Navarro-Angeles3, oscar Camacho1, Sergi Herdia4, Marta lópez-Gómez1, Silvia Gacía-Díaz1, Paola Vidal Montal5, Pol Maymó-Paituvi6, martí Aguilar-Coll7 and Javier Narváez8, 1Complex Hospitalari Universitari Moisès Broggi, Barcelona, Spain, 2Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, 3Department of Rheumatology, Complex Universitari Hospitalari Moisès Broggi, Sant Joan Despí, Barcelona, Spain, Sant Joan Despí, Barcelona, Spain, 4Complex Hospitalari Moisès Broggi, Barcelona, Spain, 5Bellvitge University Hospital, Barcelona, Spain, 6Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, 7Hospital Universitari de Bellvitge, Barcelona, Spain, 8Hospital Universitari de Bellvitge, L'Hospitalet; Barcelona, Barcelona, Spain

    Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disorder primarily targeting exocrine glands. A significant extraglandular manifestation is interstitial lung disease (ILD), which contributes to…
  • Abstract Number: 1187 • ACR Convergence 2025

    Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis

    Tulaton Sodsri1, Nattanicha Chaisrimaneepan2, Ben Thiravetyan3, Rabhas Boonyawairote4, Nopavit Mohpichai5, Nutchapon Xanthavanij6, Natnicha Jakramonpreeya7, Pintip Ngamjanyaporn8 and Tananchai Petnak8, 1Department of Medicine, Texas Tech University Health Sciences Center, Bangkok, Thailand, 2Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, 3Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, 4University of Illinois at Chicago, Chicago, 5Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 6Mount Auburn Hospital, Harvard Medical School, Cambridge, 7Chakri Naruebodindra Medical Institute, Bangkok, Thailand, 8Ramathibodi Hospital, Bangkok, Thailand

    Background/Purpose: The associations between various myositis-specific antibodies (MSAs), rapidly progressive interstitial lung disease (RP-ILD), and mortality in antisynthetase syndrome (ASS) have been previously reported in…
  • Abstract Number: 0882 • ACR Convergence 2025

    Serum KL-6 as a Predictive Biomarker for Interstitial Lung Disease Progression and Mortality in Systemic Sclerosis: A Prospective Cohort Study

    cristiana Sieiro1, Jose Ordas Martínez2, Sara Calleja Antolín2, Juan Garcia Herrero2, Javier De la Calle2, Miriam Retuerto2, Laura Sierra2, Elena Bollo de Miguel2 and Elvira Díez Álvarez2, 1Univrsity of Manchester, Manchester, United Kingdom, 2Complejo Asistencial Universitario de León, León, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in systemic sclerosis (SSc). Early detection and continuous monitoring of ILD are…
  • 1
  • 2
  • 3
  • …
  • 47
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology